LakeShore Biopharma Receives Phase III Trial Approval In China For Simplified Four-Dose YSJA Rabies Vaccine Regimen; Aims To Enhance Patient Adherence And Reduce Costs While Maintaining Immunogenicity
LakeShore Biopharma Receives Phase III Trial Approval In China For Simplified Four-Dose YSJA Rabies Vaccine Regimen; Aims To Enhance Patient Adherence And Reduce Costs While Maintaining Immunogenicity
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.